Nuvilex, Inc. (NVLX) Reports Positive Phase 2 Data for Pancreatic Cancer Treatment

QualityStocks would like to highlight Nuvilex, Inc. (PINKSHEETS: NVLX), a Green Company believing in “Good for You, Good for the Environment”. The company is expanding its natural product lines and will be making important strides in the biotechnology arena. They have acquired a treatment technology designed to combat pancreatic cancer that has completed a Phase II clinical trial.
In the company’s news yesterday,

Nuvilex today announced favorable results of a completed Phase 2 clinical trial carried out in Europe to combat pancreatic cancer. The company announced last week that it had acquired the treatment technology which involves the use of encapsulated cells.
The trial demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. Highlights of the trial, which were compared to Eli Lilly’s (NYSE: LLY) Gemzar®, the current gold standard chemotherapy, include:

• Results demonstrated a 100% increase in patients’ median survival rate;
• The 1-year survival rate was twice that observed with the current gold standard;
• Chemotherapy dose needed was only one-third the normal amount;
• Improved quality of life was noted in more than half of the patients.

In the US alone, 37,000 people die every year from pancreatic cancer. It is widely regarded as the single most aggressive form of cancer. Nuvilex is aggressively pursuing the next phase of development of this treatment technology.

NVLX closed today’s trading at $0.07, up 2.94%, on heavy volume of approximately 15 million shares. Through yesterday’s close, NVLX average daily volume over the last 3 months has been 1 million shares. At current levels, Nuvilex commands a $24.4 million market cap.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.